CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer

ConclusionsIntratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

Yicheng Ni Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized diseas...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionsBy analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Abstract Efficacy data from the KATHERINE clinical trial comparing ado-trastuzumab emtansine (T-DM1) to trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer with residual disease after neoadjuvant therapy (hazard ratio for invasive disease or death, 0.50; P
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractBackgroundAlthough recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for handling diffuse type GC are identified. Here, we aim to identify a prognostic and predictive signature predicting heterogeneous clinical courses of diffuse type GC. Table: 155PUnivariate and multivariate Cox regression analysis of overall survival in diffuse type gastric cancerVariablesUnivariateMultivariatenHR (95% CI)P-valuenHR (95% CI)P-valueAge4021.013 (1.001 - 1.025)0.0374021.02 (1.007 - 1.032)0.003Gender (Male or Female)4021.074 (0.805 - 1.433)0.625AJCC Stage (I, ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this analysis, nivo was not associated with HP in the pbo-controlled CheckMate 451 trial. These data are consistent with the previous analysis of ATTRACTION-2, suggesting that reports of HP with immunotherapy may reflect some patients ’ natural course of disease.Clinical trial identificationCheckMate 451 trial: NCT02538666.ONO-4538-12/ATTRACTION-2 trial: NCT02267343.Editorial acknowledgementStephen Gutkin and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb and ONO Pharmaceutical Co. Ltd.FundingBristol-Myers Squibb and ONO Phar...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this study, M+P demonstrated tolerability and preliminary evidence of anti-tumor activity as a chemotherapy-free regimen in 2nd line HER2+ GC; biomarker analysis suggests an association with higher expression and retention of HER2 and PD-L1 together with pre-existing anti-HER2 immunity.Clinical trial identificationNCT02689284.Legal entity responsible for the studyMacroGenics, Inc.FundingMacroGenics, Inc.DisclosureH. Park: Research grant / Funding (institution): Ambrx; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution):...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 September 2019Source: Cirugía Española (English Edition)Author(s): Carles Pericay, Ismael Macías-Declara, Virginia Arrazubi, Laia Vilà, Miguel MarínAbstractAdenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. In recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperativ...
Source: Cirugia Espanola - Category: Surgery Source Type: research
ConclusionsOur findings suggest that ANTXR1 is a promising candidate for preclinical and clinical evaluation for gastric adenocarcinoma immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma. Early indications of the four-center, phase II clinical trial are positive. The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth. The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma. The single-arm trial began i...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Song Y, Ye M, Zhou J, Wang Z, Zhu X Abstract Digestive system cancers, mainly including gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer, are major public health problems and lead to serious cancer-related deaths worldwide. Clinically, treatment strategies of these cancers include surgery, chemotherapy, and immunotherapy. Although successful resection and chemotherapeutic drugs have improved the treatment level, the survival rate of patients with advanced digestive system cancers remains still low primarily due to tumor metastasis. E-cadherin, the prototypical member of th...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Immunotherapy